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The aim here was to evaluate the evidence that might support or refute the use of intra-
articular viscosupplementation in treating patients with symptomatic knee osteoarthrosis.
A  review of the literature was conducted using the Medline, PubMed and Cochrane Con-
trolled Trial Register databases and Cochrane database systematic reviews (Cochrane
Library). Only studies presenting a high level of evidence were taken into consideration. This
study included analysis on randomized clinical trials that included at least 100 patients in
each  intervention group, meta-analyses and systematic reviews. Two meta-analyses, ﬁve
systematic reviews and six randomized clinical trials fulﬁlled the inclusion criteria for this
review. In the light of the best evidence available so far, there is no consensus for indicating
or  even for contraindicating the use of intra-articular viscosupplementation among patients
with symptomatic knee osteoarthrosis (level of evidence I and degree of recommendation
A).  Further studies with appropriate methodology are needed to elucidate this matter.
©  2014 Sociedade Brasileira de Ortopedia e Traumatologia. Published by Elsevier Editora
Ltda. All rights reserved.
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Avaliar evidências que apoiem ou refutem o uso de viscossuplementac¸ão intra-articular no
tratamento de pacientes com osteoartrose sintomática de joelho. Foi feita uma  revisão da
literatura com o uso dos bancos de dados Medline, Pubmed e Cochrane Controlled Trial
cido hialurônico Register e Cochrane Databases Systematic Reviews (Cochrane Library). Foram considerados
elevado nível de evidências. O estudo incluiu a análise de ensaios clíni-iscossuplementac¸ão apenas estudos com cos  randomizados que incluíram pelo menos 100 pacientes em cada grupo de intervenc¸ão,
metanálises e revisões sistemáticas. Duas metanálises, cinco revisões sistemáticas e seis
ensaios clínicos randomizados preencheram os critérios de inclusão desta revisão. Frente às
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melhores evidências existentes até o momento, não existe consenso para indicac¸ão e até
mesmo contraindicac¸ão do uso da viscossuplementac¸ão intra-articular em pacientes com
osteoartrose sintomática do joelho (nível de evidência I e grau de recomendac¸ão A). Futuros
estudos com metodologia adequada são necessários para elucidac¸ão dessa questão.
©  2014 Sociedade Brasileira de Ortopedia e Traumatologia. Publicado por Elsevier
Editora Ltda. Todos os direitos reservados.Introduction
Osteoarthrosis is characterized by pain and progressive joint
dysfunction resulting from destruction of the cartilage and
subchondral bone, with occurrences of reduction of the joint
space, inﬂammation/synovitis and formation of periarticular
osteophytes.1–4 Among the major joints, the knees are the
ones most affected, such that knee osteoarthrosis gives rise
to functional deﬁcits in 10% of individuals over the age of 55
years and in 25% in cases of advanced disease.5 Currently,
there are no epidemiological studies in Brazil that have pre-
cisely elucidated the prevalence of osteoarthrosis or the public
expenditure related to this disease. In view of the signiﬁcant
increase in life expectancy that has occurred in the Brazilian
population and the increasing proportion of elderly people,
osteoarthrosis needs to be considered to be a matter of public
health interest.6
Several options for conservative treatment of osteoarthro-
sis exist. These include weight reduction, physiotherapy,
physical exercise and extra-articular devices for functional
assistance. The options for pharmacological therapy (ordinary
analgesics, opioids, non-steroidal anti-inﬂammatory drugs
and corticoids) are aimed towards pain relief. Glucosamines,
diacerein and hyaluronic acid are drugs known to be modi-
ﬁers of the natural history of the disease, and these promote
improvement of functional and pain levels over the short term.
Nonetheless, further studies are needed in order to elucidate
the efﬁciency of drugs for avoiding disease progression. There
is still no effective medication for changing the course of this
disease.7,8
Synovial ﬂuid is composed of polysaccharides, among
other elements. These contain glucosamine, glucuronic acid
and hyaluronic acid, and this last substance is considered
to be a key molecule in joint biomechanics. Hyaluronic
acid is a biopolymer formed by glucuronic acid and N-
acetylglucosamine. It has a viscous texture and is found in the
synovial ﬂuid, vitreous humour and collagenous connective
tissue of numerous organisms and is an important gly-
cosaminoglycan (GAG) in constituting the joint. This molecule
is the only non-sulfated GAG. It has the capacity to become
associated with proteins in order to form molecular aggre-
gates, but it does not form proteoglycans. In joints affected
by osteoarthrosis, the concentration and molecular weight of
hyaluronic acid in the synovial ﬂuid become reduced, which
alters its properties through diminishing its viscosity and
reducing its capacity to absorb shock and provide lubrication,
and leads to damage to cartilage and increased symptoms.9–13It is believed that the mechanism of action of hyaluronic
acid in joints is related to inhibition of inﬂammatory medi-
ators and cartilage degeneration enzymes. This reducescartilage degradation and increases the production of
cartilaginous matrix.7,14 Hyaluronic acid preparations for
intra-articular use can be further divided between those of
low and high molecular weight. According to some stud-
ies, there are advantages in using the high molecular weight
presentation.7,8 Despite the possible beneﬁts of viscosupple-
mentation, its use remains controversial.
The present review had the objective of assessing the
current evidence supporting or contraindicating the use of
intra-articular viscosupplementation with hyaluronic acid for
treating knee osteoarthrosis.
Materials  and  methods
A review of the literature was conducted using the Medline,
PubMed, Cochrane Controlled Trial Register and Cochrane
Systematic Review (Cochrane Library) databases. This inves-
tigation used the keywords viscosupplementation, hyaluronic
acid, osteoarthritis, randomized, review and meta-analysis. Only
studies deﬁned as presenting high-quality evidence (level
A, according to the Oxford Centre for Evidence-Based
Medicine),15 such as systematic reviews, meta-analyses and
randomized clinical trials (RCTs), were included. The pop-
ulation of interest included patients with symptomatic
osteoarthrosis of the knee who were undergoing non-surgical
treatment for painful osteoarthrosis.
The inclusion criteria for articles were as follows:
- Systematic reviews or meta-analyses on randomized
clinical trials that assessed the use of intra-articular visco-
supplementation for treating osteoarthrosis of the knee in
humans;
- Randomized controlled clinical trials (RCTs) that compared
the use of viscosupplementation with placebo or other med-
ication, were adequately designed and included at least 100
patients in each intervention (viscosupplementation or vis-
cosupplementation and placebo).
The criteria for excluding articles were as follows:
- Studies on animals;
- Studies with fewer than 100 patients in each arm of the
intervention.
Results
Out of the 239 potentially eligible studies that were
investigated through Medline and PubMed (keywords:
viscosupplementation AND hyaluronic acid), only 13 fulﬁlled the
inclusion criteria. Of these, six were randomized clinical trials,
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Table 1 – Summaries of the randomized clinical trials (RCTs) evaluated.
Study (ref#) Level of evidence Type of study Parameters evaluated Results and conclusions
16 1 A RCT, controlled, DB
N = 253
Hylan G-F 20 versus placebo
WOMAC with pain
Evaluations after 4, 8, 12, 18
and 26 weeks
Hylan G-F 20 is safe and effective for
pain relief.
17 1 A RCT, controlled, DB
N = 306
Hyaluronic acid versus
placebo
Pain  and functional
capacity
Follow-up of 40 months
Repetition of cycles of IAHA improves
the symptoms of knee osteoarthrosis
between the cycles and also has a
good effect for at least 1 year after the
last inﬁltration.
18 1 A RCT, controlled, DB
N = 117
Hylan G-F 20 versus
physiological saline
solution
WOMAC with pain Hylan G-F was effective and better
tolerated for treating idiopathic
chronic osteoarthritis
19 1 A RCT, multicenter, open
N = 255
WOMAC with pain, adverse
effects
Hylan G-F results in beneﬁts for the
knee and for general health, thus
reducing the levels of associated
therapies (NSAIDS) and systemic
adverse reactions
20 1 A RCT, simple randomization
N = 392
Intra-articular Hylan G-F
20, sodium hyaluronate
WOMAC with pain and
patient satisfaction
Evaluated after 6 weeks and
3, 6 and 12 months
Both treatments provided pain
reduction. The clinical effectiveness
and patient satisfaction are better
after using Hylan G-F 20
21 1 A RCT, controlled, SB
N = 660
Hylan, hyaluronic acid
WOMAC with pain No evidence of differences between
Hylan and hyaluronic acid. No reason
for using Hylan in patients with
osteoarthrosis, given the cost and
local adverse effects.
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ve were systematic reviews and two were meta-analyses.
ummaries and comments relating to the studies evaluated
re presented in Tables 1 and 2.16–28
iscussion
steoarthrosis is the commonest form of arthritis in patients
ver the age of 50 years and the knees are among the joints
ost commonly affected. Because the knees are load-bearing
oints, alterations to their biomechanics lead to signiﬁcant
orbidity and functional limitation.6 With the increase in life
xpectancy of the Brazilian population, osteoarthrosis is tend-
ng to become a public health problem. No studies directed
owards evaluating the prevalence of osteoarthrosis or the
ublic expenditure involved in treating it have been conducted
n Brazil.6 In the United States, sates of medications for treat-
ng this disease had a turnover of US$ 760 million in 2004.29
The pharmacological therapeutic options for knee arthro-
is currently available have the aim of promoting pain relief
nd functional improvement. There are still no medications
vailable on the market with proven inﬂuence on the progres-
ion of the disease.7,8
In individuals with osteoarthrosis, hyaluronic acid in
he synovial ﬂuid undergoes reductions in concentration
nd molecular weight, which lead to loss of viscosity
nd, consequently, loss of the functions of lubrication and
hock absorption. This process contributes towards progres-
ion of joint degeneration and activation of inﬂammatory
athways.13,30 Viscosupplementation with hyaluronic acidHA, intra-articular hyaluronic acid; SB, single-blinding.
was developed in order to promote longer-lasting pain relief
and functional recovery, and to delay disease progression.17
Different mechanisms have been proposed for explaining
its effect, such as stimulation of production of endoge-
nous hyaluronic acid, suppression of degradation of the
cartilaginous matrix and suppression of the inﬂammatory
response to interleukin-1. To further increase the viscosity of
hyaluronic acid and diminish joint clearance, chemically mod-
iﬁed hyaluronic acid compounds were created such that they
would have higher molecular weights (around 23 × 107 Da) and
also a longer half-life, which would theoretically increase the
potential and duration of its effect.31–35
In a multicenter randomized controlled clinical trial with
40 months of follow-up, named the Amelia Project, Navarro-
Sarabia et al.17 evaluated 306 patients over the age of 45
years who presented knee osteoarthrosis (Kellgren–Lawrence
grades II and III, with a minimum joint space of 2 mm). Four
cycles of intra-articular injection of hyaluronic acid or placebo
were performed. The patients were evaluated with regard to
clinical and functional improvement and side effects. These
authors concluded that the treatment was safe and that there
were signiﬁcant improvements in functional capacity and
symptoms, in relation to the control group, with an effect that
was maintained even 1 year after the last application.17
Chevalier et al.16 evaluated 253 patients over the age of
40 years who presented symptomatic primary osteoarthrosis
of the knee, in a multicenter double-blind randomized study
with 26 weeks of follow-up. The patients received a single
application of a high molecular weight compound (Hylan G-
F 20) or placebo. The safety of the treatment and the clinical
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Table 2 – Summary of the meta-analysis and systematic review studies evaluated.
Study (ref#) Level of evidence Type of study Parameters evaluated Results and conclusions
22 1 A Systematic review
5 case series and 13 RCTs
High molecular weight HA
Pain High molecular weight HA is effective for
treating continuous pain in patients with
knee osteoarthrosis. Its action has a slower
start but longer effects than those of
intra-articular steroids.
23 1 A Systematic review
14 studies
HA, placebo, sodium
hyaluronate
WOMAC with pain and
functional capacity
Use of HA is not recommended in patients
with symptomatic knee osteoarthritis
24 1 A Systematic review
9 RCTs
Intra-articular HA versus
placebo
Pain
Evaluated 1, 5–7, 8–12 and
15–22 weeks after HA
injection
HA has a modest effect on pain in patients
with knee osteoarthritis, 5–7 and 8–10 weeks
after the injection, but has no effect after
15–22 weeks.
25 1 A Systematic review
7 RCTs, 6 case series and 1
cross-sectional study
Hylan G-F 20, placebo,
NSAIDS, sodium
hyaluronate
Pain and functional
capacity of the knee
Hylan G-F improves pain and functional
capacity of knees over the short term.
26 1 A Systematic review
67 RCTs
Several classes of HA versus
placebo
Pain and functional
capacity of the knee
Viscosupplementation is effective in treating
knee osteoarthritis; it reduces the pain and
improves functional capacity.
27 1 A Meta-analysis
29  RCTs
IAHA approved in the
United States
Pain  and functional
capacity
4–13 and 14–26 weeks after
inﬁltration
IAHA is safe and effective in patients with
symptomatic knee osteoarthritis
28 1 A Meta-analysis
89 studies
HA or derivative, placebo
Pain and functional
capacity
The beneﬁt of viscosupplementation for
improving pain and functional capacity in
the knee is minimal or non-existent. Its use
should be discouraged given the greater local
adverse effects.
id; IARCT, randomized clinical trial; DB, double blinding; HA, hyaluronic ac
repercussion (WOMAC index) were evaluated and the authors
concluded that the treatment was safe and that there was
a signiﬁcant clinical improvement among the patients who
underwent viscosupplementation.
Like in the abovementioned study, in a multicenter ran-
domized study conducted by Raynauld et al.,19 255 patients
who  received high molecular weight hyaluronic acid or
placebo were evaluated over a 1-year period. These authors
found a signiﬁcant difference (greater than 20% in the
WOMAC score) between their groups, which demonstrates
that there were beneﬁts from viscosupplementation. In other
randomized controlled trials that used high molecular weight
hyaluronic acid (which are listed in Table 1), it was also con-
cluded that there were signiﬁcant clinical improvements.18
With regard to the molecular weight of the hyaluronic acid
to be used, two studies compared the use of high and low
molecular weight hyaluronic acid for treating osteoarthrosis.
According to Raman et al.,20 use of high-weight hyaluronic
acid (Hylan G-F 20) has the advantage of a more  long-lasting
effect, but with clinical efﬁcacy and tolerability similar to other
presentations. In a clinical trial that compared three presenta-
tions of hyaluronic acid for treating osteoarthrosis of the knee,
Jüni et al.21 concluded that the different molecular weightsHA, intra-articular hyaluronic acid.
of hyaluronic acid did not give rise to any signiﬁcant differ-
ences.
In a systematic review of 76 studies of medium quality,
Bellamy et al.26 came to the conclusion that viscosup-
plementation was safe and led to signiﬁcant clinical and
functional improvements, in comparison with placebo. They
also reported that the effect of this treatment was longer-
lasting than that of intra-articular corticosteroids. Many  of the
studies included in their review presented design inadequa-
cies.
Aggarwal and Sempowski22 reviewed ﬁve case series and 13
randomized controlled trials and concluded that use of visco-
supplementation for treating mild to moderate osteoarthrosis
of the knee, with high molecular weight hyaluronic acid,
showed signiﬁcant beneﬁts in relation to clinical improve-
ment and durability of effect. They also demonstrated that
the patients had good tolerability towards the treatment and,
in comparison with use of intra-articular corticoids, the peak
action occurred later and the effect was longer-lasting. Miller
et al.27 analyzed the effect and safety of viscosupplementa-
tion in patients with osteoarthrosis of the knee and gathered
together a sample of 4866 individuals in 29 randomized clin-
ical trials. Studies with design inadequacies or insufﬁcient
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ample size were excluded. These authors concluded that vis-
osupplementation was effective for achieving clinical and
unctional improvements, as well as being safe.
In a meta-analysis, Rutjes et al.28 evaluated 89 studies and
2,667 participants with knee osteoarthrosis. Their conclu-
ion was that, because of lack of evidence of any signiﬁcant
linical and functional improvement, along with the potential
isk of severe adverse effects viscosupplementation should be
iscouraged for treating knee arthrosis.
According to the 2013 guidelines for treating osteoarthro-
is of the knee,23 published by the American Academy of
rthopaedic Surgeons (AAOS) after a meta-analysis that
nvolved 14 randomized controlled trials, there is strong
vidence for not recommending the use of intra-articular
yaluronic acid, because all the studies that made compar-
sons with a control group showed uncertainty regarding
ractical clinical application of the treatment. Five of the
even studies evaluated that related to molecular weight pre-
ented patients who  perhaps would not represent the general
ondition of the population with knee osteoarthrosis. This
eta-analysis was criticized in the study by Miller et al.27
ecause of confusion in the data analysis and use of com-
ounds that had not been approved in the United States.
inal  remarks
he pattern of osteoarthrosis treatment using hyaluronic acid
s extremely variable between studies. There are differences in
he preparations used, number of applications, dose injected
er application and number of cycles used, in addition to time
ifferences between them. The proﬁle of the patients analyzed
n each study also varied, such that some presented young
atients with mild arthrosis and others, elderly patients with
evere arthrosis. The parameters for analyzing clinical and
unctional improvements also changed between the studies.
any of them did not have a control group and there is also
 lack of studies comparing viscosupplementation with other
reatments. Most of the studies are of poor quality with inad-
quate designs.
onclusion
n the light of the evidence that currently exists, there is still no
olid basis for indicating or even for contraindicating the use of
ntra-articular viscosupplementation with hyaluronic acid or
ts derivatives for treating symptomatic knee osteoarthrosis.
onﬂicts  of  interest
he authors declare no conﬂicts of interest.
 e  f  e  r  e  n  c  e  s
1. Dieppe PA, Lohmander LS. Pathogenesis and management of
pain in osteoarthritis. Lancet. 2005;365(9463):965–73.
2. Holbrook A.M. (Chair) for the Ontario Musculoskeletal
Therapy Review Panel. In: Ontario treatment guidelines for
osteoarthritis, rheumatoid arthritis, and acute
2;5 0(5):489–494 493
musculoskeletal injury. Toronto: Queen’s Printer of Ontario;
2000.
3. Badley E, DesMeules M. Arthritis in Canada: an ongoing
challenge. Ottawa: Health Canadá; 2003.
4. Felson DT. An update on the pathogenesis and epidemiology
of  osteoarthritis. Radiol Clin North Am. 2002;42(1):1–9.
5. Peat G, McCarney R, Croft P. Knee pain and osteoarthritis in
older adults: a review of community burden and current use
of  primary health care. Ann Rheum Dis. 2001;60(2):91–7.
6. Ministério da Saúde do Brasil. Rede Interagencial de
Informac¸ões para a Saúde. Available at:
http://tabnet.datasus.gov.br/cgi/idb2009/matriz.htm.
7.  American College of Rheumatology Subcommittee on
Osteoarthritis Guidelines. Recommendations for the medical
management of osteoarthritis of the hip and knee: 2000
update. Arthritis Rheum. 2000;43(9):1905–15.
8. Manek NJ, Lane NE. Osteoarthritis: current concepts in
diagnosis and management. Am Fam Physician.
2000;61(6):1795–804.
9. Ayral X. Injections in the treatment of osteoarthritis. Best
Pract Res Clin Rheumatol. 2001;15(4):609–26.
0. George E. Intra-articular hyaluronan treatment for
osteoarthritis. Ann Rheum Dis. 1998;57(11):637–40.
1. Simon LS. Viscosupplementation therapy with intra-articular
hyaluronic acid. Fact or fantasy? Rheum Dis Clin North Am.
1999;25(2):345–57.
2. Fam H, Bryant JT, Kontopoulou M. Rheological properties of
synovial ﬂuids. Biorheology. 2007;44(2):59–74.
3. Dahl LB, Dahl IM, Engström-Laurent A, Granath K.
Concentration and molecular weight of sodium hyaluronate
in synovial ﬂuid from patients with rheumatoid arthritis and
other arthropathies. Ann Rheum Dis. 1985;44(12):817–22.
4. Wen DY. Intra-articular hyaluronic acid injections for knee
osteoarthritis. Am Fam Physician. 2000;62(3):565–70.
5. Oxford Centre for Evidence-Based Medicine. Available at:
http://www.cebm.net/index.aspx?o=5653.
6. Chevalier X, Jerosch J, Goupille P, Van Dijk N, Luyten FP, Scott
DL,  et al. Single, intra-articular treatment with 6 ml  hylan G-F
20  in patients with symptomatic primary osteoarthritis of the
knee: a randomised, multicentre, double-blind, placebo
controlled trial. Ann Rheum Dis. 2010;69(1):113–9.
7. Navarro-Sarabia F, Coronel P, Collantes E, Navarro FJ, De la
Serna AR, Naranjo A, et al. A 40-month multicentre,
randomised placebo-controlled study to assess the efﬁcacy
and  carry-over effect of repeated intra-articular injections of
hyaluronic acid in knee osteoarthritis: the Amelia project.
Ann Rheum Dis. 2011;70(11):1957–62.
8. Wobig M, Dickhut A, Maier R, Vetter G. Viscosupplementation
with hylan G-F 20: a 26-week controlled trial of efﬁcacy and
safety in the osteoarthritic knee. Clin Ther. 1998;20(3):410–23.
9. Raynauld JP, Torrance GW, Band PA, Goldsmith CH, Tugwell P,
Walker  V, et al. A prospective, randomized, pragmatic, health
outcomes trial evaluating the incorporation of hylan G-F 20
into the treatment paradigm for patients with knee
osteoarthritis (part 1 of 2): clinical results. Osteoarthritis
Cartilage. 2002;10(7):506–17.
0. Raman R, Dutta A, Day N, Sharma HK, Shaw CJ, Johnson GV.
Efﬁcacy of hylan G-F 20 and sodium hyaluronate in the
treatment of osteoarthritis of the knee – a prospective
randomized clinical trial. Knee. 2008;15(4):318–24.
1. Jüni P, Reichenbach S, Trelle S, Tschannen B, Wandel S, Jordi
B,  et al. Viscosupplementation Trial Group. Efﬁcacy and safety
of  intraarticular hylan or hyaluronic acids for osteoarthritis of
the  knee: a randomized controlled trial. Arthritis Rheum.
2007;56(11):3610–9.2. Aggarwal A, Sempowski IP. Hyaluronic acid injections for
knee osteoarthritis. Systematic review of the literature. Can
Fam Physician. 2004;50:249–56.
p . 2 0 
2
2
2
2
2
2
2
3
3
3
3
3494  r e v b r a s o r t o 
3. Treatment of osteoarthritis of the knee – evidence-based
guideline. 2nd ed. Rosemont: American Academy of
Orthopaedic Surgeons; 2013.
4. Modawal A, Ferrer M, Choi HK, Castle JA. Hyaluronic acid
injections relieve knee pain. J Fam Pract. 2005;54(9):
758–67.
5. Espallargues M, Pons JM. Efﬁcacy and safety of
viscosupplementation with Hylan G-F 20 for the treatment of
knee osteoarthritis: a systematic review. Int J Technol Assess
Health Care. 2003;19(1):41–56.
6. Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G.
Viscosupplementation for the treatment of osteoarthritis of
the knee. Cochrane Database Syst Rev. 2006;(2):CD005321.
7. Miller LE, Block JE. US-approved intra-articular hyaluronic
acid injections are safe and effective in patients with knee
osteoarthritis: systematic review and meta-analysis of
randomized, saline-controlled trials. Clin Med Insights
Arthritis Musculoskelet Disord. 2013;6:57–63.
8. Rutjes AW, Jüni P, Da Costa BR, Trelle S, Nüesch E,
Reichenbach S. Viscosupplementation for osteoarthritis of
the knee: a systematic review and meta-analysis. Adv Intern
Med. 2012;157(3):180–91.
9. United States Commetee on Health, Education, Labor, and
Pensions. Subcommittee on Aging. Centre of Disease Control’s
31 5;5 0(5):489–494
role in combating the burden of arthritis. Washington:
Department of Health and Human Services; 2004.
0. Balazs EA, Denlinger JL. Viscosupplementation: a new
concept in the treatment of osteoarthritis. J Rheumatol Suppl.
1993;39:3–9.
1. Smith MM, Ghosh P. The synthesis of hyaluronic acid by
human synovial ﬁbroblasts is inﬂuenced by the nature of the
hyaluronate in the extracellular environment. Rheumatol Int.
1987;7(3):113–22.
2. Bagga H, Burkhardt D, Sambrook P, March L. Longterm effects
of  intraarticular hyaluronan on synovial ﬂuid in osteoarthritis
of the knee. J Rheumatol. 2006:946–50.
3. Ghosh P. The role of hyaluronic acid (hyaluronan) in health
and disease: interactions with cells, cartilage, and
components of synovial ﬂuid. Clin Exp Rheumatol.
1994;12(1):75–82.
4. Yasui T, Akatsuka M, Tobetto K, Hayaishi M, Ando T. The
effect of hyaluronan on interleukin-1 alpha-induced
prostaglandin E2 production in human osteoarthritic synovial
cells. Agents Actions. 1992;37(1–2):155–6.5. Monfort J, Nacher M, Montell E, Vila J, Verges J, Benito P.
Chondroitin sulfate and hyaluronic acid (500–730 kDa) inhibit
stromelysin-1 synthesis in human osteoarthritic
chondrocytes. Drugs Exp Clin Res. 2005;31(2):71–6.
